Drug Profile
Pneumococcal vaccine - Tianjin CanSino Biotechnology
Alternative Names: PBPV vaccineLatest Information Update: 23 Nov 2022
Price :
$50
*
At a glance
- Originator Tianjin CanSino Biotechnology
- Class Pneumococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Pneumococcal infections
Most Recent Events
- 23 Nov 2022 Tianjin CanSino Biotechnology plans a phase I trial in Pneumococcal infections (In volunteers, Prevention) in China (IM, Injection) in December 2024 (NCT05622942)
- 07 Nov 2022 Pneumococcal vaccine - Tianjin CanSino Biotechnology is still in early stage clinical development for Pneumococcal infections in China (CanSino Biotechnology pipeline, November 2022)(NCT04087460)
- 30 Jun 2022 CanSino Biologics completes a phase Ia trial in Pneumococcal infections (Prevention) in China (IM) (NCT04087460)